We are live on ! Find out more
Frazier Life Sciences Management

Frazier Life Sciences Management Portfolio holdings

AUM $4.03B Turnover 19.15%
1-Year Est. Return 94.69%
 

Frazier Life Sciences is a biotech investment firm that backs companies developing new drugs, from their formation through to public markets. It started operations in 2022 and is owned mainly by Jamie Topper and Patrick Heron. Its Public Fund invests mainly in listed drug and biotech companies, with up to a fifth of its portfolio available for financings of private ones, while the firm's other funds mostly back private companies.

This Fund
S&P 500
This Quarter Est. Return
+24.25%
1 Year Est. Return
+94.69%
3 Year Est. Return
+692.48%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.59B
AUM Growth
+$706M
Cap. Flow
-$31.5M
Cap. Flow %
-0.69%
Top 10 Hldgs %
73.61%
Holding
44
New
6
Increased
8
Reduced
2
Closed
3
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$6.14B
$899M 19.58%
7,679,684
– –
2022 Q1
17 quarters
NAMS icon
2
NewAmsterdam Pharma
NAMS
$2.42B
$613M 13.35%
18,088,902
+1,145,128
+7% +$37.7M
2022 Q4
14 quarters
ERAS icon
3
Erasca
ERAS
$5.5B
$458M 9.96%
24,975,188
+300,000
+1% +$4.29M
2024 Q2
8 quarters
MBX icon
4
MBX Biosciences
MBX
$2.78B
$367M 8%
6,652,013
– –
2024 Q3
7 quarters
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.57B
$259M 5.64%
9,874,511
– –
2022 Q1
17 quarters
TRVI icon
6
Trevi Therapeutics
TRVI
$1.95B
$185M 4.04%
9,939,447
-100
-0% -$1.45K
2022 Q2
16 quarters
KRYS icon
7
Krystal Biotech
KRYS
$9.05B
$179M 3.9%
481,307
– –
2022 Q1
17 quarters
MAZE icon
8
Maze Therapeutics
MAZE
$1.88B
$150M 3.27%
5,032,915
+465,641
+10% +$12.2M
2025 Q1
5 quarters
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$493M
$135M 2.95%
12,466,489
– –
2022 Q1
17 quarters
PVLA icon
10
Palvella Therapeutics
PVLA
$2.11B
$135M 2.94%
882,400
– –
2024 Q3
7 quarters
BBIO icon
11
BridgeBio Pharma
BBIO
$15.3B
$115M 2.51%
1,548,139
-1,900,000
-55% -$133M
2023 Q1
13 quarters
IRON icon
12
Disc Medicine
IRON
$3.49B
$99.1M 2.16%
1,354,852
– –
2023 Q2
12 quarters
CYTK icon
13
Cytokinetics
CYTK
$7.82B
$98.8M 2.15%
1,159,879
– –
2025 Q2
4 quarters
DYN icon
14
Dyne Therapeutics
DYN
$3.13B
$70M 1.53%
3,153,082
– –
2025 Q1
5 quarters
ASND icon
15
Ascendis Pharma
ASND
$17.8B
$60.1M 1.31%
225,155
+91,822
+69% +$21.4M
2024 Q3
7 quarters
SVRA icon
16
Savara
SVRA
$984M
$59.9M 1.3%
9,720,852
– –
2023 Q3
11 quarters
PBLS
17
Parabilis Medicines
PBLS
$3.56B
$52.6M 1.14%
+1,920,805
New +$53.1M
2026 Q2
0 quarters
AURA icon
18
Aura Biosciences
AURA
$740M
$50.4M 1.1%
7,100,000
+2,000,000
+39% +$14.3M
2025 Q2
4 quarters
QUIT icon
19
Achieve Life Sciences
QUIT
$695M
$49.7M 1.08%
+7,614,836
New +$36.3M
2026 Q2
0 quarters
VOR icon
20
Vor Biopharma
VOR
$1.17B
$46.8M 1.02%
2,543,939
– –
2025 Q4
2 quarters
ALLO icon
21
Allogene Therapeutics
ALLO
$291M
$46.7M 1.02%
22,446,668
+18,650,000
+491% +$41M
2024 Q1
9 quarters
TARS icon
22
Tarsus Pharmaceuticals
TARS
$3.96B
$45.9M 1%
728,644
– –
2022 Q1
17 quarters
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$1.96B
$40.1M 0.87%
4,009,240
– –
2026 Q1
1 quarter
ALKS icon
24
Alkermes
ALKS
$7.9B
$36.7M 0.8%
700,647
– –
2024 Q3
7 quarters
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$3.23B
$36.4M 0.79%
1,438,198
– –
2025 Q3
3 quarters

Similar funds

Frazier Life Sciences Management's Q2 2026 Portfolio in Review

As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines: 1,920,805 shares worth $52.6M.
  • Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
  • Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
  • Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $100M.
  • Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
  • Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
  • Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.